Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China

Overview of attention for article published in OncoTargets and therapy, June 2020

Altmetric Badge

Mentioned by

reddit: 1 Redditor

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 11 Mendeley

Summary Reddit Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China

Article in Translational Lung Cancer Research (October 2022)

Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung Cancer

Preprint in medRxiv (December 2021)

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Article in Frontiers in Oncology (May 2021)